Will Myopia Cause Blindness?
Real Risk Explained Clearly
Short answer: Most people with myopia — including high myopia — do not go blind. But the risk of serious vision-threatening complications rises progressively with axial length, and the difference between −3D and −10D is not just a number on a prescription — it is a meaningful difference in lifetime eye health risk.
What myopia actually does to the eye
Myopia is not just a prescription — it is a structural condition where the eyeball is physically longer than it should be. This stretching of the eye thins the retina, choroid, and sclera at the back of the eye. The longer the eye, the thinner these layers become, and the higher the mechanical stress on the retinal tissue.
This physical thinning is what causes the elevated risk of complications — not the diopter number itself, but the underlying axial length that drives it.
What are the real risks?
Myopic maculopathy
Myopic maculopathy (damage to the central retina, or macula) is the leading cause of vision impairment specifically attributable to myopia. It includes conditions like lacquer cracks, myopic choroidal neovascularisation, and macular atrophy. Risk rises steeply with axial length: an eye at 28mm has several times the macular complication risk of one at 24mm.
Retinal detachment
A stretched, thinned retina is more prone to tears and detachment — particularly around the periphery. High myopia carries approximately 3–5× the lifetime risk of retinal detachment compared to emmetropia. Retinal detachment can cause permanent vision loss if not treated urgently with surgery.
Glaucoma
High myopia is associated with elevated intraocular pressure sensitivity and structural optic nerve changes that increase glaucoma risk. Myopic eyes also show lower measured IOP relative to actual pressure, making glaucoma harder to detect in standard screening.
Cataracts
High myopia increases lifetime risk of nuclear cataracts, typically occurring earlier than in non-myopic eyes. While cataract surgery is highly effective, it carries additional risk in long eyes including higher rates of retinal complications during and after surgery.
Risk by axial length
| Axial length | Approximate prescription | Risk category | Key concern |
|---|---|---|---|
| <24mm | 0 to −1D | Low | Baseline risk, no specific concern |
| 24–25mm | −1 to −3D | Mild | Monitor; risk remains close to population baseline |
| 25–26mm | −3 to −5D | Moderate | Elevated retinal risk; annual dilated exam advised |
| 26–28mm | −5 to −8D | High | 5× higher retinal detachment risk; maculopathy screening |
| >28mm | >−8D | Very high | Significant maculopathy risk; specialised monitoring required |
Axial length to prescription mapping is approximate — varies by corneal curvature and lens. Based on Tideman et al. 2016, Flitcroft 2012.
Does the prescription number matter — or is it axial length?
Axial length is the more direct risk predictor. Two people can have the same −5D prescription but very different axial lengths (and therefore different risk profiles) depending on their corneal curvature. This is why modern myopia management focuses on measuring and tracking axial length in millimetres, not just prescription in diopters.
A person with −5D from a steep cornea may have a 24mm axial length (relatively low risk). A person with −5D from a long eye may have a 26.5mm axial length (meaningfully higher risk). The prescription alone does not reveal this.
How does myopia management reduce this risk?
By slowing axial elongation during childhood — when the eye is growing fastest — myopia management reduces the final adult axial length. Every 0.1mm of avoided growth translates to a small but real reduction in lifetime complication risk. Treatments like MiSight® (55% AL reduction) and Stellest® (67% AL reduction) can, over 10+ years of childhood, make the difference between an adult eye at 25mm vs 27mm — which is a clinically meaningful difference in lifetime risk.
Where does your child's axial length put them?
Enter age, axial length, and ethnicity to see their percentile, growth rate, and projected AL at age 18 with and without treatment.
Check risk level →Free · No login · Under 30 seconds
This page is for educational purposes and does not constitute medical advice. MyopiaTracker is a decision-support tool — not a diagnostic device. MiSight® is a registered trademark of The Cooper Companies. Stellest® is a registered trademark of Essilor International. MiyoSmart® is a registered trademark of Hoya Corporation. Treatment availability and regulatory approval vary by country. Consult a qualified optometrist or ophthalmologist for personalised advice.